GILT, Human, mAb MaP.IP30
Antibodies derived from clone MAP.IP30 recognize human gamma-interferon-inducible lysosomal thiol reductase (GILT). GILT facilitates major histocompatibility complex (MHC) class II-restricted processing through reduction of protein disulfide bonds in the endocytic pathway. GILT can also facilitate the transfer of disulfide-containing antigens into the cytosol, enhancing their cross-presentation by MHC class I.
Human GILT consists of 261 amino acids with a 37 amino acid signal sequence and a 224 amino acid precursor form. In general, the 35 kDa precursor is tagged with mannose-6- phosphate (M6P) residues and transported to the endocytic pathway via the M6P receptor (M6PR). A small fraction of the precursor is secreted as a disulfide-linked dimer. In early endosomes, N- and C-terminal pro-peptides are cleaved to generate a 28 kDa mature form. The mature form of GILT is localized to late endosomes and lysosomes and has maximal reductase activity at the acidic pH found in these compartments. GILT is constitutively expressed in professional antigen presenting cells (APC). The constitutive expression of GILT in APCs is likely to account for enhanced reduction of proteins in the late endosomal, lysosomal, and phagosomal compartments. A combination of GILT-mediated reduction and proteolysis in the these compartments can enhance the generation of class II epitopes as well as facilitate the translocation of internalized antigens into the cytosol for proteosomal processing and cross-presentation. The protein is also constitutively expressed in thymocytes, mature T cells, and some fibroblasts. IFN-g plays is the key factor in inducing expression of MHC class II and other components of the class II-restricted processing pathway. IFN-g signals through a specific cell surface receptor followed by activation of JAK/STAT1 signalling.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA